334 related articles for article (PubMed ID: 18093206)
1. Treatment of lentigo maligna with imiquimod before staged excision.
Cotter MA; McKenna JK; Bowen GM
Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
3. Topical imiquimod therapy for lentigo maligna.
Mahoney MH; Joseph MG; Temple C
Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
[TBL] [Abstract][Full Text] [Related]
4. Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
Donigan JM; Hyde MA; Goldgar DE; Hadley ML; Bowling M; Bowen GM
JAMA Dermatol; 2018 Aug; 154(8):885-889. PubMed ID: 29847610
[TBL] [Abstract][Full Text] [Related]
5. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.
Powell AM; Russell-Jones R
J Am Acad Dermatol; 2004 May; 50(5):792-6. PubMed ID: 15097969
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of treatment of lentigo maligna with 5% imiquimod cream.
Fleming CJ; Bryden AM; Evans A; Dawe RS; Ibbotson SH
Br J Dermatol; 2004 Aug; 151(2):485-8. PubMed ID: 15327559
[TBL] [Abstract][Full Text] [Related]
8. Treatment of lentigo maligna with imiquimod 5% cream.
Hopson B; Richey D; Sajben FP
J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
[TBL] [Abstract][Full Text] [Related]
9. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports.
Spenny ML; Walford J; Werchniak AE; Beltrani V; Brennick JB; Storm CA; Perry AE; Chapman MS
Cutis; 2007 Feb; 79(2):149-52. PubMed ID: 17388218
[TBL] [Abstract][Full Text] [Related]
10. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
[TBL] [Abstract][Full Text] [Related]
11. [Imiquimod treatment of lentigo maligna to dermoscopic and histologic clearance].
Lorentzen HF; Weismann K
Ugeskr Laeger; 2005 Sep; 167(39):3696-7. PubMed ID: 16219219
[TBL] [Abstract][Full Text] [Related]
12. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients.
Van Meurs T; Van Doorn R; Kirtschig G
Dermatol Surg; 2010 Jun; 36(6):853-8. PubMed ID: 20618370
[TBL] [Abstract][Full Text] [Related]
13. Topical 5% imiquimod in the treatment of lentigo maligna.
Wong JG; Toole JW; Demers AA; Musto G; Wiseman MC
J Cutan Med Surg; 2012; 16(4):245-9. PubMed ID: 22784516
[TBL] [Abstract][Full Text] [Related]
14. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
15. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
Wolf IH; Cerroni L; Kodama K; Kerl H
Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
[TBL] [Abstract][Full Text] [Related]
17. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.
Kirtschig G; van Meurs T; van Doorn R
Acta Derm Venereol; 2015 Jan; 95(1):83-5. PubMed ID: 24696093
[TBL] [Abstract][Full Text] [Related]
18. Topical imiquimod for periocular lentigo maligna.
Demirci H; Shields CL; Bianciotto CG; Shields JA
Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
Powell AM; Robson AM; Russell-Jones R; Barlow RJ
Br J Dermatol; 2009 May; 160(5):994-8. PubMed ID: 19222462
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients.
Ly L; Kelly JW; O'Keefe R; Sutton T; Dowling JP; Swain S; Byrne M; Curr N; Wolfe R; Chamberlain A; Haskett M
Arch Dermatol; 2011 Oct; 147(10):1191-5. PubMed ID: 22006136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
